Roger Seheult, MD of MedCram on how Fluvoxamine Maleate, an affordable SSRI medication FDA authorized in 1994, was revealed to lower COVID 19 hospitalizations and deaths in a current randomized placebo managed trial released in the Lancet. Fluvoxamine (Luvox) was likewise compared to other medications such as ivermectin, metformin, and hydroxychloroquine in the trial. This is Update 138 in the MedCram Coronavirus Series
(This video was taped on November 1, 2021)
TOPICS IN THIS VIDEO INCLUDE:
00: 00 What is Fluvoxamine, how is it working to deal with COVID-19 clients, and how did we get here?
00: 42 JAMA Study from Nov. 2020: Fluvoxamine vs. Placebo and Clinical Deterioration in Patients with Symptomatic COVID-19
01: 27 Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI): How do SSRIs work?
02: 37 History of Fluvoxamine and recognized negative effects
03: 39 Why would scientists attempt an SSRI (Fluvoxamine) for COVID-19? Reviewing the function of Reactive Oxygen Species (ROS) and inflammatory elements
08: 03 Breaking down the information from the smaller sized JAMA research study on Fluvoxamine
10: 36 Large-scale TOGETHER COVID-19 medical trials: Is there a medication currently in usage that could be repurposed for SARS-CoV-2 treatment?
12: 11 Medications studied in TOGETHER trial: Hydroxychloroquine, Lopinavir/Ritonavir, Metformin, Ivermectin, Doxazosin, Interferon Lambda, and Fluvoxamine
13: 36 Ivermectin trial information
14: 07 Fluvoxamine trial information: statistically considerable at avoiding hospitalization
Roger Seheult, MD is the co-founder and lead teacher at https://www.medcram.com
He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.
LINKS/ REFERENCES:
Fluvoxamine in the treatment of stress and anxiety conditions (PMC)| https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424117/
Effect of early treatment with fluvoxamine on danger of emergency situation care and hospitalisation amongst clients with COVID-19: the TOGETHER randomised, platform medical trial (Lancet)| https://www.thelancet.com/journals/langlo/article/PIIS2214-109 X(21)00448 -4/ fulltext
Who We Are (Together Trial)| https://www.togethertrial.com/who-we-are
The Sigma-1 Receptor in Cellular Stress Signaling (Frontiers in Neuroscience)| https://www.frontiersin.org/articles/103389/ fnins.201900733/ complete
All coronavirus updates are at MedCram.com (consisting of more conversation on the COVID delta variation, fluvoxamine maleate, serotonin syndrome, fluvoxamine 100 mg, vaccine randomized trial and more).
SUBSCRIBE TO THE MEDCRAM YOUTUBE CHANNEL:
http://covid19globalcases.com/fluvoxamine-a-4-antidepressant-that-reduces-covid-19-hospitalizations/
Comments
Post a Comment